Catalyst Pharmaceuticals (NASDAQ:CPRX) Raised to Hold at ValuEngine

ValuEngine upgraded shares of Catalyst Pharmaceuticals (NASDAQ:CPRX) from a sell rating to a hold rating in a research note published on Tuesday, October 15th, ValuEngine reports.

A number of other analysts have also recently weighed in on the stock. BidaskClub upgraded shares of Catalyst Pharmaceuticals from a buy rating to a strong-buy rating in a report on Saturday, August 3rd. Piper Jaffray Companies set a $8.00 price target on shares of Catalyst Pharmaceuticals and gave the company a buy rating in a report on Wednesday, October 9th. SunTrust Banks reiterated a buy rating and issued a $11.00 target price (up from $9.00) on shares of Catalyst Pharmaceuticals in a research note on Thursday, August 8th. Cantor Fitzgerald lifted their target price on shares of Catalyst Pharmaceuticals from $10.00 to $12.00 in a research note on Thursday, August 8th. Finally, Zacks Investment Research upgraded shares of Catalyst Pharmaceuticals from a hold rating to a buy rating and set a $5.75 target price for the company in a research note on Wednesday, July 31st. One research analyst has rated the stock with a sell rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Catalyst Pharmaceuticals presently has a consensus rating of Buy and an average target price of $8.63.

NASDAQ:CPRX traded up $0.41 during mid-day trading on Tuesday, hitting $5.07. 1,780,200 shares of the company’s stock were exchanged, compared to its average volume of 1,998,751. Catalyst Pharmaceuticals has a one year low of $1.85 and a one year high of $7.67. The company has a market cap of $477.90 million, a PE ratio of -15.36 and a beta of 2.37. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.09 and a quick ratio of 5.07. The business has a fifty day moving average price of $5.18 and a 200 day moving average price of $4.81.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last released its quarterly earnings results on Wednesday, August 7th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating analysts’ consensus estimates of $0.03 by $0.07. The firm had revenue of $28.84 million during the quarter, compared to the consensus estimate of $17.99 million. During the same quarter in the prior year, the business posted ($0.06) earnings per share. The firm’s quarterly revenue was up 2883900.0% on a year-over-year basis. On average, equities analysts forecast that Catalyst Pharmaceuticals will post 0.34 EPS for the current fiscal year.

In related news, Director Charles B. O’keeffe bought 10,000 shares of the stock in a transaction that occurred on Friday, October 11th. The stock was bought at an average cost of $4.70 per share, for a total transaction of $47,000.00. Following the purchase, the director now directly owns 553,376 shares of the company’s stock, valued at $2,600,867.20. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 10.70% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Tower Research Capital LLC TRC acquired a new stake in Catalyst Pharmaceuticals during the 3rd quarter valued at approximately $27,000. Creative Planning acquired a new stake in Catalyst Pharmaceuticals during the 3rd quarter valued at approximately $84,000. Emerald Mutual Fund Advisers Trust acquired a new stake in Catalyst Pharmaceuticals during the 3rd quarter valued at approximately $5,752,000. Emerald Advisers LLC acquired a new stake in Catalyst Pharmaceuticals during the 3rd quarter valued at approximately $6,244,000. Finally, California Public Employees Retirement System lifted its stake in Catalyst Pharmaceuticals by 106.8% during the 3rd quarter. California Public Employees Retirement System now owns 136,253 shares of the biopharmaceutical company’s stock valued at $724,000 after acquiring an additional 70,358 shares during the period. Institutional investors and hedge funds own 60.21% of the company’s stock.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome in the United States.

See Also: Return on Investment (ROI) Defined, Explained

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.